<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Clinical Practice</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Clinical Practice</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиническая практика</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-3095</issn><issn publication-format="electronic">2618-8627</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">690296</article-id><article-id pub-id-type="doi">10.17816/clinpract690296</article-id><article-id pub-id-type="edn">SGMBVH</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Primary femoro-popliteal-tibiofibular bypass in patients with critical limb ischemia in the era of endovascular surgery</article-title><trans-title-group xml:lang="ru"><trans-title>Первичное шунтирование при поражении артерий бедренно-подколенно-берцового сегмента у пациентов с критической ишемией нижних конечностей в эру эндоваскулярной хирургии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8414-6810</contrib-id><contrib-id contrib-id-type="spin">5406-0730</contrib-id><name-alternatives><name xml:lang="en"><surname>Burov</surname><given-names>Alexander Yu.</given-names></name><name xml:lang="ru"><surname>Буров</surname><given-names>Александр Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>burovalexander93@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0628-7378</contrib-id><contrib-id contrib-id-type="spin">6274-0640</contrib-id><name-alternatives><name xml:lang="en"><surname>Lysenko</surname><given-names>Evgenii R.</given-names></name><name xml:lang="ru"><surname>Лысенко</surname><given-names>Евгений Рудольфович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>д-р мед. наук</p></bio><email>angioler@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2286-3419</contrib-id><contrib-id contrib-id-type="spin">9664-0255</contrib-id><name-alternatives><name xml:lang="en"><surname>Gryaznov</surname><given-names>Oleg G.</given-names></name><name xml:lang="ru"><surname>Грязнов</surname><given-names>Олег Германович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>zigphrid@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9577-3414</contrib-id><contrib-id contrib-id-type="spin">2088-7527</contrib-id><name-alternatives><name xml:lang="en"><surname>Gulyaeva</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Гуляева</surname><given-names>Елена Вадимовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>strelochka_l@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-8313-8677</contrib-id><name-alternatives><name xml:lang="en"><surname>Abasov</surname><given-names>Radzhab B.</given-names></name><name xml:lang="ru"><surname>Абасов</surname><given-names>Раджаб Баширович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>abasov_119@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-2079-6645</contrib-id><contrib-id contrib-id-type="spin">4238-2538</contrib-id><name-alternatives><name xml:lang="en"><surname>Knyazeva</surname><given-names>Karina A.</given-names></name><name xml:lang="ru"><surname>Князева</surname><given-names>Карина Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>knyazeva.carina@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-2780-3504</contrib-id><contrib-id contrib-id-type="spin">1310-8994</contrib-id><name-alternatives><name xml:lang="en"><surname>Malyutina</surname><given-names>Elena D.</given-names></name><name xml:lang="ru"><surname>Малютина</surname><given-names>Елена Дмитриевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>д-р мед. наук</p></bio><email>edmalutina@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-3294-1538</contrib-id><contrib-id contrib-id-type="spin">4800-3150</contrib-id><name-alternatives><name xml:lang="en"><surname>Islyamov</surname><given-names>Emil R.</given-names></name><name xml:lang="ru"><surname>Ислямов</surname><given-names>Эмиль Рустемович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>islyamov.emil.99@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Federal Clinical Center for High Medical Technologies of the Federal Medical and Biological Agency</institution></aff><aff><institution xml:lang="ru">Федеральный клинический центр высоких медицинских технологий Федерального медико-биологического агентства</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-10-06" publication-format="electronic"><day>06</day><month>10</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-10-26" publication-format="electronic"><day>26</day><month>10</month><year>2025</year></pub-date><volume>16</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>30</fpage><lpage>37</lpage><history><date date-type="received" iso-8601-date="2025-09-11"><day>11</day><month>09</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-09-14"><day>14</day><month>09</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://clinpractice.ru/clinpractice/article/view/690296">https://clinpractice.ru/clinpractice/article/view/690296</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold> In the majority of patients with critical ischemia in the lower limbs, the findings include the «multi-level» atherosclerotic lesions in the arteries of the femoral-popliteal-tibiofibular segment. The optimal method of re-vascularisation in this cohort of patients is not defined as of today. <bold>AIM:</bold> To evaluate the efficiency of conducting the initial autovenous tibiofibular bypass surgery in case of lesions in the arteries of the femoral-popliteal-tibiofibular segment in patients with critical ischemia of the lower limbs. <bold>METHODS:</bold> The analysis included the results of the initial tibiofibular autovenous bypass surgeries, performed in 112 patients at the Federal State Budgetary Institution «Federal Clinical Center of High Medical Technologies» under the Russian Federal Medical-Biological Agency during the period from 2010 until 2021, of which 25 (22.3%) individuals had the stage III chronic arterial insufficiency in the lower limbs, 87 (77.7%) — stage IV acc. to the Fountain–Pokrovsky classification. The distribution by the atherosclerotic lesion in arteries of the lower limbs with taking into consideration the TASC II classification was the following: type C — in 9 (8.0%), type D — in 103 (92.0%). <bold>RESULTS:</bold> Within the 30 days period, 4 (3.6%) patients have shown the presence of unfavorable cardio-vascular events, 3 (2.7%) cases resulted in the early high amputation. The perioperative mortality rate was 2.7% (n=3). The primary passability of the tibiofibular autovenous bypass was 91%, 76% and 67% in 1, 3 and 5 years, while the secondary passability was 93%, 80% and 71%; the limb survival rate was 98%, 86% and 81,5%; the overall survival of the patients was 88.5%, 81% and 70%, respectively. <bold>CONCLUSION:</bold> The initial tibiofibular autovenous bypass surgeries (bypass first) represent the effective and safe method of surgical treatment for atherosclerotic lesions in the arteries of the femoral-popliteal-tibiofibular segment in patients with critical ischemia of the lower limbs. Open-access surgeries in the era of endovascular surgery can be used as the first line therapy with comparable direct and remote results.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> У большинства пациентов с критической ишемией нижних конечностей выявляется «многоэтажное» атеросклеротическое поражение артерий бедренно-подколенно-берцового сегмента. Оптимальный метод реваскуляризации у данной когорты пациентов на сегодняшний день не определён. <bold>Цель</bold> — оценить эффективность выполнения первичного аутовенозного берцового шунтирования при поражении артерий бедренно-подколенно-берцового сегмента у пациентов с критической ишемией нижних конечностей. <bold>Методы.</bold> Проанализированы результаты первичных берцовых аутовенозных шунтирований, выполненных 112 пациентам в ФГБУ ФКЦ ВМТ ФМБА России в период с 2010 по 2021 год, из них 25 (22,3%) человек имели III стадию хронической артериальной недостаточности нижних конечностей, 87 (77,7%) — IV стадию по классификации Фонтейна–Покровского. Распределение по атеросклеротическому поражению артерий нижних конечностей с учётом классификации TASC II было следующим: тип C — у 9 (8,0%), тип D — у 103 (92,0%). <bold>Результаты.</bold> В течение 30-дневного срока у 4 (3,6%) пациентов были выявлены неблагоприятные сердечно-сосудистые события, в 3 (2,7%) случаях выполнена ранняя высокая ампутация. Периоперационная смертность — 2,7% (n=3). Через 1, 3 и 5 лет первичная проходимость берцовых аутовенозных шунтирований составила 91%, 76% и 67%, в то время как вторичная проходимость — 93%, 80% и 71%; показатель сохранения конечности — 98%, 86% и 81,5%; общая выживаемость пациентов — 88,5%, 81% и 70% соответственно. <bold>Заключение.</bold> Первичные берцовые аутовенозные шунтирования являются эффективным и безопасным методом хирургического лечения атеросклеротического поражения артерий бедренно-подколенно-берцового сегмента у пациентов с критической ишемией нижних конечностей. Открытые хирургические операции в эру эндоваскулярной хирургии могут быть использованы в качестве первой линии терапии с сопоставимыми непосредственными и отдалёнными результатами.</p></trans-abstract><kwd-group xml:lang="en"><kwd>critical ischemia of the lower limbs</kwd><kwd>femoral-popliteal-tibiofibular arterial segment</kwd><kwd>tibiofibular autovenous bypassing</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>критическая ишемия нижних конечностей</kwd><kwd>бедренно-подколенно-берцовый артериальный сегмент</kwd><kwd>берцовое аутовенозное шунтирование</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>GBD 2019 Peripheral Artery Disease Collaborators. Global burden of peripheral artery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease study 2019. Lancet Glob Health. 2023;11(10):e1553–e1565. doi: 10.1016/S2214-109X(23)00355-8</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Lin J, Chen Y, Jiang N, et al. Burden of peripheral artery disease and its attributable risk factors in 204 countries and territories from 1990 to 2019. Front Cardiovasc Med. 2022;9:868370. doi: 10.3389/fcvm.2022.868370 EDN: ABVZUS</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. doi: 10.1016/j.jacc.2020.11.010 EDN: IQJFIO</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Sigvant B, Lundin F, Wahlberg E. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2016;51(3):395–403. doi: 10.1016/j.ejvs.2015.10.022 EDN: CYANPM</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Simon F, Oberhuber A, Floros N, et al. Pathophysiology of chronic limb ischemia. Gefasschirurgie. 2018;23(Suppl 1):13–18. doi: 10.1007/s00772-018-0380-1 EDN: ZMSEOK</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Fabiani I, Calogero E, Pugliese NR, et al. Critical limb ischemia: a practical up-to-date review. Angiology. 2018;69(6):465–474. doi: 10.1177/0003319717739387</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Anand SS, Caron F, Eikelboom JW, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018;71(20):2306–2315. doi: 10.1016/j.jacc.2018.03.008 EDN: VTHMBQ</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Agnelli G, Belch JJ, Baumgartner I, et al. Morbidity and mortality associated with atherosclerotic peripheral artery disease: a systematic review. Atherosclerosis. 2020;293:94–100. doi: 10.1016/j.atherosclerosis.2019.09.012 EDN: RDYDUP</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Van Netten JJ, Fortington LV, Hinchliffe RJ, Hijmans JM. Early post-operative mortality after major lower limb amputation: a systematic review of population and regional based studies. Eur J Vasc Endovasc Surg. 2016;51(2):248–257. doi: 10.1016/j.ejvs.2015.10.001</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Conte MS, Bradbury AW, Kolh P, et al.; GVG Writing Group. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S):3S–125S.e40. doi: 10.1016/j.jvs.2019.02.016 EDN: ZWNXMR</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>The TASC Steering Committee; Jaff MR, White CJ, Hiatt WR, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II). J Endovasc Ther. 2015;22(5):663–677. doi: 10.1177/1526602815592206</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Farber A, Menard MT, Conte MS, et al.; BEST-CLI Investigators. Surgery or endovascular therapy for chronic limb-threatening ischemia. N Engl J Med. 2022;387(25):2305–2316. doi: 10.1056/NEJMoa2207899 EDN: VBMMRU</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Bradbury AW, Moakes CA, Popplewell M, et al.; BASIL-2 Investigators. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. Lancet. 2023;401(10390):1798–1809. doi: 10.1016/S0140-6736(23)00462-2</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Norgren L, Patel MR, Hiatt WR, et al. Outcomes of patients with critical limb ischaemia in the EUCLID trial. Eur J Vasc Endovasc Surg. 2018;55(1):109–117. doi: 10.1016/j.ejvs.2017.11.006 EDN: YDSBZB</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Uccioli L, Meloni M, Izzo V, et al. Critical limb ischemia: current challenges and future prospects. Vasc Health Risk Manag. 2018;14:63–74. doi: 10.2147/VHRM.S125065</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Biancari F, Salenius JP, Heikkinen M, et al. Risk-scoring method for prediction of 30-day postoperative outcome after infrainguinal surgical revascularization for critical lower-limb ischemia: a finnvasc registry study. World J Surg. 2007;31(1):217–225; discussion 226-227. doi: 10.1007/s00268-006-0242-y EDN: PTNLOC</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Simons JP, Schanzer A, Flahive JM, et al. Survival prediction in patients with chronic limb-threatening ischemia who undergo infrainguinal revascularization. Eur J Vasc Endovasc Surg. 2019;58(1S):120–134. doi: 10.1016/j.ejvs.2019.04.009</mixed-citation></ref></ref-list></back></article>
